Naramig (Naratriptan)

Naratriptan, the active ingredient in Naramig, is a Triptan (selective 5‑HT1B/1D receptor agonist) presented as an oral dosage form for systemic use. It is employed for the acute treatment of migraine attacks in adults and is intended to relieve headache pain and associated symptoms such as nausea and photophobia.

GNH USA supplies Naramig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures product quality through rigorous quality‑assurance processes and provides regulatory support for import and distribution in multiple regions.

Naratriptan is a Triptan that targets the serotonergic pathway involved in migraine attacks.

- Migraine without aura: provides rapid relief of headache pain and associated symptoms. - Migraine with aura: alleviates the headache phase that follows the aura. - Acute migraine attacks: reduces the duration and severity of an attack when taken early.

Naratriptan may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Dizziness: transient light‑headedness or unsteadiness. - Fatigue: unusual tiredness or lack of energy. - Dry mouth: reduced salivation leading to throat discomfort. - Tingling sensations: paresthesia in extremities. - Chest discomfort: mild pressure or tightness.

Serious or Rare Side Effects: - Coronary vasospasm: sudden narrowing of coronary arteries. - Serotonin syndrome: potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Severe hypertension: abrupt increase in blood pressure. - Allergic reactions: rash, swelling, or anaphylaxis. - Myocardial infarction: rare heart attack events. - Stroke: extremely rare cerebrovascular events.

Before prescribing Naratriptan, clinicians should evaluate patient‑specific risk factors and contraindications.

- Cardiovascular assessment: avoid use in patients with uncontrolled hypertension or known coronary artery disease. - Concomitant triptans: do not combine with other triptan agents to prevent additive vasoconstriction. - Medication overuse: limit use to avoid rebound headache. - Hepatic impairment: use caution and consider dose adjustment in patients with liver dysfunction. - Drug interactions: review all current medications for potential serotonergic effects. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Naratriptan can interact with several drug classes, requiring careful review of a patient’s medication list.

Major Interactions (Avoid): - Ergotamine derivatives: risk of severe vasospasm. - Monoamine oxidase inhibitors (MAOIs): increased serotonergic activity. - Selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs): heightened risk of serotonin syndrome. - Other triptans: additive vasoconstrictive effects. - Strong CYP3A4 inhibitors: may raise plasma concentrations of Naratriptan.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible enhancement of blood‑pressure‑lowering effect. - Tricyclic antidepressants (TCAs): may increase serotonergic side effects. - Oral contraceptives: may modestly affect migraine frequency and response.